View this email in your browser

BTP Quarterly Update

December 18, 2019

The mission of the University of Minnesota Brain Tumor Program (UMBTP) is to continually distinguish itself as a national leader in the field of neuro-oncology by combining the principles of outstanding clinical care and education with cutting edge research.

The group consists of many dedicated researchers and clinicians of numerous disciplines and specialties. These disciplines and specialties include - but are not limited to - cancer genetics, neuro-oncology, neurosurgery, pharmacy, biomedical engineering, and veterinary medicine. 

Here's what we've been up to for the last few months:
Clark Chen, MD, PhD, was highlighted in the article "Clinical Trial Gives Hope to Glioblastoma Patients" on the Medical School Website, December 13, 2019. 
Chris Moertel, MD, and Mike Olin, PhD, were highlighted in the article "Researchers working on groundbreaking treatment for brain tumors at M Health Fairview University of Minnesota Masonic Children's Hospital" on Fox 9 News, December 9, 2019. 
Clark Chen, MD, PhD, was highlighted in the article "Team Uses Glass Beads, Ultrasound To Shatter Brain Cancer Cells" in ScienceBlog, October 4, 2019. This work was also highlighted in "The 'Goldilocks' Principle for Curing Brain Cancer" articles on the University of Minnesota Medical School News, October 4, 2019.
William Elmquist, PhD, PharmD, was highlighted in the article "Two foundations combine efforts against childhood cancer" in Lake Geneva Regional News, October 2, 2019.
The Hyundai Scholar Hope grant was presented to Chris Moertel, MD, September 2019. This was highlighted in the article "Hyundai Hope on Wheels Presents University of Minnesota Masonic Children's Hospital with $300,000 Hyundai Scholar Hope Grant to Support Pediatric Cancer Research" on the Hyundai Hope on Wheels website.


Sara Osum, PhD candidate, gave platform presentation entitled "Investigating the role of NF1 +/- haploinsufficient fibroblasts in neurofibromatosis type 1-associated tumors" at the Annual Neurofibromatosis Conference, San Francisco, CA, September 2019. 

Mike Olin, PhD, gave presentation entitled "Emerging Target Therapies in Cancer: Toward effective combinations," Santa Maria, Cuba, October 2019.

Mike Olin, PhD, gave presentation entitled "Overpowering multiple inhibitory immune checkpoints with a single peptide inhibitor enhanced survival in a spontaneous high-grade glioma canine pilot-trial" at the SNO-SCIDOT Joint Conference on Therapeutic Delivery to the CNS, Phoenix, AZ, November 2019.

Clark Chen, MD, PhD, gave presentations entitled "Immuno-stimulation through surgically administered mechanical high intensity focused ultrasound" and "Interim results of a phase II multi-center study of oncolytic adenovirus DNX-2401 with pembrolizumab for recurrent glioblastoma; CAPTIVE study" and "Clinical Applicaation of GammaTile in Neuro-Oncology: Initial experience" at the Society for Neuro-Oncology Meeting, Phoenix, AZ, November 2019.

Kathryn Dusenbery, MD, gave presentation entitled "First experience with GammaTile permanent implants for recurrent brain tumors at University of Minnesota" at the Society for Neuro-Oncology Meeting, Phoenix, AZ, November 2019.

David Largaespada, PhD, gave presentation entitled "Using transposon mutagenesis and synthetic lethal screens to find therapeutic targets for sarcoma" at Cedars-Sinai Medical Center, Los Angeles, CA, November 2019. 


David Largaespada receives grant entitled "Predictive Modeling Utilizing a Preclinical NF1-MPNST Platform Suitable for Precision Oncology" from the NF Research Initiative, Division of Genetics and Genomics: MPNST Patient-Derived Model Development and Testing Centers Grant, December 1, 2019.

Clark Chen receives R01 grant entitled "Development of Quantitative Deuterium MRS Imaging for Human Brain Tumor Application at Ultrahigh Field" from the NIH, 2019. 

Clark Chen receives grant entitled "Natural Killer (NK) cells as a platform for glioblastoma therapy" from the Ferris Foundation Research Fund, 2019.


Laser Ablation of Abnormal Neurological Tissue using Robotic Neuroblate System (LAANTERN). Sponsor: Monteris

A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) with Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma. Sponsor: DNATrix therapeutics

MEGA-PRESS in glioma. Sponsor: Investigator initiated

Phase I of Ad-RTS-hIL-12 in glioblastoma. Sponsor: Ziopharm

A phase II, open-label, multi-center study of ONC201 in adults with recurrent high-grade glioma. Sponsor: Oncoceutics


Evans E, Nascene D, Sommer K, Moertel C. "Autonomic Cross-Innervation in Patients With Neurofibromatosis Type 2: Frey Syndrome and Unilateral Epiphora with Rhinorrhea." Child Neurol Open. 2019 Aug 6; 6: 2329048X19866617.

Huang M, Tailor J, Zhen Q, Gilmor AH, Miller ML, Weishaupt H, Chen J, Zheng T, Nash EK, McHenry LK, An Z, Ye F, Takashima Y, Clarke J, Ayetey H, Cavalli FMG, Luu B, Moriarity BS, Ilkhanizadeh S, Chavez L, Yu C, Kurian KM, Magnaldo T, Sevenet N, Koch P, Pollard SM, Dirks P, Snyder MP, Largaespada DA, Cho YJ, Phillips JJ, Swartling FJ, Morrissy AS, Kool M, Pfister SM, Taylor MD, Smith A, Weiss WA. "Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis." Cell Stem Cell. 2019 Sep 5; 25(3): 433-446.

Hou JC, Shamsan GA, Anderson SM, McMahon MM, Tyler LP, Castle BT, Heussner RK, Provenzano PP, Keefe DF, Barocas VH, Odde DJ. "Modeling distributed forces within cell adhesions of varying size on continuous substrates." Cytoskeleton (Hoboken). 2019 Sep 12.

Chahal KK, LI J, kufareva I, Parle M, Durden DL, Wechsler-Reya RJ, Chen CC, Abagyan R. "Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma." PLoS One. 2019 Sep 20; 14(9): e0214901.

Cornax I, Pluhar GE, Clark HB, O'Sullivan MG. "Oligodendroglioma with Neuronal Differentiation in Two Boxer Dogs." J Comp Pathol. 2019 Oct; 172: 11-16.

Bartek J Jr, Alattar AA< Dhawan S, Ma J, Koga T, Nakaji P, Dusenbery KE, Chen CC. "Receipt of brachytherapy is an independent predictor of survival in glioblastoma in the Surveillance, Epidemiology, and End Results database." J Neurooncol. 2019 Oct; 145(1): 75-83.

Hemmat M, Castle BT, Sachs JN, Odde DJ. "Multiscale Computational Modeling of Tubulin-Tubulin Lateral Interaction." Biophys J. 2019 Oct 1; 117(7): 1234-1249.

Liu CJ, Shamsan GA, Akkin T, Odde DJ. "Glioma Cell Migration Dynamics in Brain Tissue Assessed by Multimodal Optical Imaging." Biophys J. 2019 Oct 1; 117(7): 1179-1188.

Shamsan GA, Odde DJ. "Emerging technologies in mechanotransduction research." Curr Opin Chem Bio. 2019 Oct 13; 53: 125-130.

Xiong Z, Ampudia Mesias E, Pluhar GE, Rathe SK, Largaespada DA, Sham YY, Moertel CL, Olin MR. "CD200 Checkpoint Reversal: A Novel Approach to Immunotherapy." Clin Cancer Res. 2019 Oct 17.

Ricard JA, Cramer SW, Charles R, Gil Tommee C, Le A, Bell WR, Chen CC, Flanagan ME. "Infratentorial Glioblastoma Metastasis to Bone." World Neurosurg. 2019 Nov; 131: 90-94.

Randall EC, Lopez BGC, Peng S, Regan MS, Abdelmoula WM, Basu SS, Santagata S, Yoon H, Haigis M, Agar JN, Tran NL, Elmquist WF, White FM, Sarkaria JN, Agar NYR. "Localized metabolomic gradients in patient-derived xenograft models of glioblastoma." Cancer Res. 2019 Nov 25.

Kim M, Laramy JK, Gampa G, Parrish KE, Brundage R, Sarkaria JN, Elmquist WF. "Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR4058: Implications for Use in Brain Tumor Therapy." Drug Metab Dispos. 2019 Dec; 47(12): 1403-1414.

Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, Koga T, Varki NM, Fenton TR, Nagahashi Marie SK, Lindahl E, Gahman TC, Shiau AK, Zhou H, DeGroot J, Sulman EP, Cavenee WK, Kolodner RD, Chen CC, Furnari FB. "Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair." Cancer Cell. 2019 Dec 9; 36(6): 690-691.

Past Events

The Brain Tumor Program Team participated in the American Brain Tumor Association's Brain Tumor 5K on Oct. 12, 2019.

Upcoming Events

Jan 9 - BTP Data Club, TBD
Feb 13 - BTP Data Club, Malgorzata Marjanska, PhD
Feb 15 - Cupid Undie Run
March 12 - BTP Data Club, Tomoyuki Koga, MD, PhD
April 6-7 - Neuro-Oncology Symposium

In Memorium

One of our friends and colleagues, Bryant J. Keller, passed away on Sunday, December 8, from an aneurysm. He was in the 5th year of his PhD training in the MCDB&G program. He will be greatly missed. 
Submit content for next newsletter
Copyright © 2019 University of Minnesota Brain Tumor Program, All rights reserved.
You are receiving this email because you opted in at our website, at a recent event, or are a member/affiliate of a BTP lab at the University of Minnesota. 
To ensure continued delivery, add to your safe senders list or address book.

Our mailing address is:
Brain Tumor Program
2231 6th St SE
CCRB 3-115
Minneapolis, MN 55455


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
University of Minnesota Brain Tumor Program · 420 Delaware St. SE · MMC 484 · Minneapolis, MN 55455-0001 · USA

Email Marketing Powered by Mailchimp